Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor.Clinical trial results from competitors were largely underwhelming, including this week’s ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Eli Lilly ( LLY 0.53%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, and it's probably going to succeed. Here's why. The juggernaut is picking up speed ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...